A phase I study of
dasatinib in children and adolescents with chronic myeloid leukemia (CML) and other malignancies determined dosing for further studies and suggested the drug is well tolerated and effective in these patients.
Not exact matches
The researchers observed that two drugs each killed a large fraction of the cells that had begun transitioning:
dasatinib, a drug that targets the Src Family Kinase (SFK) and RK20449, a new drug
in pre-clinical testing that specifically targets one of the SFK proteins called Hck.
The researchers confirmed these findings
in a mammary carcinoma mouse model — treatment with
dasatinib just a few days after administering two high doses of chemotherapy prevented tumor growth and increased survival rates.
Researchers found that genetically disrupting this pathway, or using the FDA - approved Src kinase inhibitor
dasatinib, increases PUMA levels and decreases tumor progression and metastasis
in mice by up to fivefold.
Other drugs that work
in a similar way to
dasatinib are also under investigation by Professor Winder's team.
Because
dasatinib is already cleared for clinical use, researchers hope that progress can be made more quickly towards trialling the drug
in humans as a treatment for DMD.
Those fish treated with
dasatinib were able to swim further and for longer than those
in a control group.
In contrast, because of the high incidence of TP53 mutations in the HPV - inactive class, these tumors may be less responsive to the standard cisplatin chemotherapy and more sensitive to other chemotherapies such as dasatinib.&raqu
In contrast, because of the high incidence of TP53 mutations
in the HPV - inactive class, these tumors may be less responsive to the standard cisplatin chemotherapy and more sensitive to other chemotherapies such as dasatinib.&raqu
in the HPV - inactive class, these tumors may be less responsive to the standard cisplatin chemotherapy and more sensitive to other chemotherapies such as
dasatinib.»
In one report, a patient with an L576P KIT mutation in whom imatinib therapy had previously failed experienced marked reduction in tumor burden in response to dasatinib treatmen
In one report, a patient with an L576P KIT mutation
in whom imatinib therapy had previously failed experienced marked reduction in tumor burden in response to dasatinib treatmen
in whom imatinib therapy had previously failed experienced marked reduction
in tumor burden in response to dasatinib treatmen
in tumor burden
in response to dasatinib treatmen
in response to
dasatinib treatment.
[68] Other KIT inhibitors, such as sorafenib,
dasatinib, and sunitinib, have also been reported to have beneficial effects
in mucosal melanomas harboring KIT mutations.
A drug called
dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published
in the Journal of Clinical Oncology.
The adenosine triphosphate (ATP)-- competitive kinase inhibitors imatinib (STI571; trade name: Gleevec),
dasatinib, and nilotinib inhibit multiple tyrosine kinases
in addition to ABL1 and ABL2 (5).
«If
dasatinib or nilotinib can beat Gleevec
in the response they elicit, they will offer patients even greater protection from relapse and possibly even better survival,» he said.
This discovery led him to evaluate second generation Abl kinase inhibitors, such as the dual Src / Abl inhibitor
dasatinib, which received fast - track approval at the FDA
in June 2006.
He has played a key role
in the discovery and development of multiple approved drugs, including imatinib (Gleevec),
dasatinib (Sprycel), and enzalutamide (Xtandi).